Registered title, quoted from ClinicalTrials.gov
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06355739, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
3 years to 18 years; sex: all
Registered eligibility fields
Complete marrow response (MRD>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy
Inclusion criterion 2
Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥
Inclusion criterion 3
Lansky score ≥60;
Inclusion criterion 6
Creatinine ≤1.5×ULN;
Inclusion criterion 8
Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-
Inclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06355739, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
1, age 3-18 years old (including boundary value), male and female;
- The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic
Patients with tumors who meet one of the following conditions:
- Complete marrow response (MRD>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy
Complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment)
Patients, did not turn negative after treatment);
- Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥
12 months) and did not achieve complete remission after 1 course of standard induction regimen (MRD>1%);
- Recurrence after bone marrow transplantation;
- Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined
recrudescence
- Lansky score ≥60;
4, the treatment related antigen test result is positive (CD19/CD20/CD22);
- The expected survival period from the signing date of the informed consent is more than 3 months;
6, HGB≥70g/L (blood transfusion);
7, liver and kidney function, cardiopulmonary function meet the following requirements:
- Creatinine ≤1.5×ULN;
- Left ventricular ejection fraction ≥50%;
- Blood oxygen saturation >90%;
- Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-
Exclusion Criteria:
- 1, severe cardiac insufficiency, left ventricular ejection fraction <50%;
2, have a history of severe lung function impairment;
- Combined with other advanced malignant tumors;
4, combined with serious infection and can not be effectively controlled;
5, combined with serious autoimmune disease or congenital immune deficiency;
6, active hepatitis (hepatitis B virus deoxyribonucleic acid [HBVDNA] or hepatitis C virus ribonucleic acid [HCVRNA] positive);
7, human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;
- Have a history of severe allergy to biological products (including antibiotics);
- Patients with allogeneic hematopoietic stem cell transplantation still had acute graft-versus-host response (GvHD) one month after immunosuppressant discontinuation;
10, the presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.
Quoted from ClinicalTrials.gov, NCT06355739, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06355739, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.